lesinurad/allopurinol (Discontinued)

Brand and Other Names:Duzallo (DSC)
  • Print

Dosing & Uses


Dosage Forms & Strengths

April 2019: Product discontinued by manufacturer


  • 200 mg/200 mg
  • 200 mg/300 mg


Indicated for hyperuricemia associated with gout in patients who have not achieved target serum uric acid (sUA) levels with allopurinol alone

Use 1 tablet of lesinurad/allopurinol equivalent to the total daily dose (TDD) of allopurinol; maintain TDD of allopurinol when initiating lesinurad/allopurinol

Recommended combination dose based on current allopurinol

  • For patients who have not achieved target sUA on a medically appropriate dose of allopurinol >300 mg, lesinurad/allopurinol may be initiated by using 1 tablet in place of an equivalent portion of the TDD of allopurinol
  • Allopurinol 300 mg: Initiate 1 tablet of lesinurad 200 mg/allopurinol 300 mg PO qDay
  • Allopurinol 200 mg: Initiate 1 tablet of lesinurad 200 mg/allopurinol 200 mg PO qDay
  • Lesinurad coadministered with allopurinol: Initiate 1 tablet PO qDay equivalent to the daily lesinurad and allopurinol doses

Dosage Modifications

Renal impairment

  • Mild-to-moderate (CrCl ≥45 mL/min): No dosage adjustment necessary; monitor CrCl more frequently if CrCl <60 mL/min
  • Moderate-to-severe (CrCl 30-45 mL/min): Do not initiate; discontinued if CrCl is persistently <45 mL/min while taking lesinurad/allopurinol
  • Severe renal impairment (CrCl <30 mL/min), end-stage renal disease, kidney transplant recipients, or patients on dialysis: Contraindicated
  • See Black Box Warnings

Hepatic impairment

  • Mild-to-moderate (Child-Pugh A and B): No dosage adjustment necessary
  • Severe (Child-Pugh C): Safety and efficacy not established

Gout flares

  • Gout flares may occur after initiation of urate-lowering therapy, including lesinurad/allopurinol, owing to changing sUA levels resulting in mobilization of urate from tissue deposits
  • Patients not previously taking lesinurad: Gout flare prophylaxis is recommended when initiating treatment, according to practice guidelines
  • If a gout flare occurs during treatment, lesinurad/allopurinol need not be discontinued; gout flare should be managed concurrently, as appropriate for the individual patient

Dosing Considerations

Limitation of use: Not recommended for treatment of asymptomatic hyperuricemia

1 tablet of lesinurad/allopurinol contains the maximum daily lesinurad dose (200 mg)

Do not take more than 1 tablet of lesinurad/allopurinol per day

Do not combine lesinurad/allopurinol with additional lesinurad

Safety and efficacy not established

No dosage adjustment necessary



Interaction Checker

and lesinurad/allopurinol

No Results

     activity indicator 
    No Interactions Found
    Interactions Found


      Serious - Use Alternative

        Significant - Monitor Closely


            All Interactions Sort By:
             activity indicator 
            Due to system maintenance, the drug interactions feature you are attempting to access is temporarily unavailable. Please try again later.

            Adverse Effects


            Serum creatinine elevation 1.5 x to <2.0 x baseline, lesinurad 400 mg/allopurinol (11%)


            Blood creatinine, lesinurad 400 mg/allopurinol (8%)

            Serum creatinine elevation ≥2.0 x baseline, lesinurad 400 mg/allopurinol (7%)

            Influenza, lesinurad 200 mg/allopurinol (4.9%)

            Serum creatinine elevation 1.5 x to <2.0 x baseline, lesinurad 200 mg/allopurinol (4.4%)

            Headache, lesinurad 200 mg/allopurinol (4.2%)

            Blood creatinine elevation, lesinurad 200 mg/allopurinol (3.7%)

            Renal failure, lesinurad 400 mg/allopurinol (3.5%)

            Gastroesophageal reflux disease (3.2%)

            Nephrolithiasis, lesinurad 400 mg/allopurinol (2.2%)

            Major adverse cardiovascular events (eg, cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke), lesinurad 400 mg/allopurinol (1.85%)

            Serum creatinine elevation ≥2.0 x baseline, lesinurad 200 mg/allopurinol (1.5%)

            Renal failure, lesinurad 200 mg/allopurinol (1%)


            Major adverse cardiovascular events, lesinurad 200 mg/allopurinol (0.61%)

            Nephrolithiasis, lesinurad 200 mg/allopurinol (0.5%)

            Frequency Not Defined

            ALT increased

            AST increased

            Blood alkaline phosphatase increased


            Maculopapular rash



            Postmarketing Reports

            Most common

            • Gastrointestinal disorders: Diarrhea, nausea
            • Investigations: Blood alkaline phosphatase increased, AST increased, ALT increased
            • Skin and subcutaneous tissue disorders: Rash, maculopapular rash

            Less common (<1%)

            • Blood and lymphatic system disorders: Ecchymosis, thrombocytopenia, eosinophilia, leukocytosis, leukopenia
            • Gastrointestinal disorders: Vomiting, abdominal pain, gastritis, dyspepsia
            • General disorders and administration site conditions: Pyrexia
            • Hepatobiliary disorders: Hepatitis (including hepatic necrosis and granulomatous hepatitis), hepatomegaly, hyperbilirubinemia, cholestatic jaundice
            • Musculoskeletal and connective-tissue disorders: Myopathy, arthralgia
            • Nervous system disorders: Headache, peripheral neuropathy, neuritis, paresthesia, somnolence, ageusia
            • Renal and urinary disorders: Renal failure, azotemia
            • Respiratory, thoracic and mediastinal disorders: Epistaxis
            • Skin and subcutaneous tissue disorders: Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, leukocytoclastic vasculitis, purpura, bullous dermatitis, exfoliative dermatitis, eczema, pruritus, urticaria, alopecia, onycholysis, lichen planus
            • Vascular disorders: Necrotizing vasculitis, vasculitis


            Black Box Warnings

            Acute renal failure reported with lesinurad and more commonly occurs when administered as monotherapy; lesinurad should be used in combination with a xanthine oxidase inhibitor; adverse reactions related to renal function, including acute renal failure, reported after initiating

            Lesinurad 200 mg in combination with allopurinol associated with increased incidence of serum creatinine (Scr) elevations, mostly reversible Interrupt treatment if Scr increases to >2 times baseline; discontinue treatment if CrCl <45 mL/min

            Interrupt treatment and measure Scr promptly if symptoms of acute uric acid nephropathy (eg, flank pain, nausea or vomiting) occur

            Do not restart lesinurad/allopurinol unless an alternative cause of serum creatinine abnormalities is found

            Evaluate renal function before treatment and periodically thereafter as clinically indicated; more frequent renal function monitoring recommended with CrCL < 60 mL/min or with Scr increases 1.5-2x baseline


            Severe renal impairment (CrCl <30 mL/min), end-stage renal disease, kidney transplant recipients, or patient on dialysis

            Tumor lysis syndrome or Lesch-Nyhan syndrome

            Known hypersensitivity to allopurinol, including previous occurrence of skin rash


            Increase risk of renal events; see Black Box Warnings

            Few cases reported of reversible clinical hepatoxicity with patients taking allopurinol; if anorexia, weight loss, or pruritus develops in patients on lesinurad/allopurinol, liver function should be evaluated; in patients with pre-existing liver disease, periodic liver function tests are recommended

            In clinical trials with lesinurad/allopurinol, major adverse cardiovascular events (eg, cardiovascular deaths, nonfatal myocardial infarctions, and nonfatal strokes) were observed

            Occasional occurrence of drowsiness was reported in patients taking allopurinol; caution when engaging in activities where alertness is mandatory

            Bone marrow depression has been reported in patients receiving allopurinol, most of whom received concomitant drugs with the potential for causing this reaction, ranging from 6 weeks to 6 years after initiating allopurinol therapy; see Drug interactions overview

            Rash and hypersensitivity

            • Rash frequently reported in allopurinol patients; in some instances, a skin rash may be followed by more severe hypersensitivity reactions associated with exfoliation, fever, lymphadenopathy, arthralgia, and/or eosinophilia, including Stevens-Johnson syndrome and toxic epidermal necrolysis; treatment should be discontinued immediately at any appearance of skin rash or other allergic signs/symptoms
            • Hypersensitivity reactions to allopurinol may be increased in patients with decreased renal function receiving thiazide diuretics and lesinurad/allopurinol concurrently; caution with coadministration of such combinations and patients should be observed closely

            Drug interactions overview

            • Lesinurad is a substrate of CYP2C9, OAT1, and OAT3; no clinical studies have been conducted with OAT1/OAT3 inhibitors; caution with moderate CYP2C9 inhibitors or inducers
            • Lesinurad is a weak inducer of CYP3A and has no relevant effect on any other CYP enzyme for induction (CYP1A2, CYP2C8, CYP2C9, CYP2B6, or CYP2C19) or inhibition (CYP1A2, CYP2B6, CYP2D6, CYP2C8, CYP2C9, CYP2C19, or CYP3A4); monitor for potential reduction in efficacy in CYP3A substrates
            • Reported that allopurinol prolongs the half-life of dicumarol, a coumarin anticoagulant; prothrombin time should be reassessed periodically in patients receiving coumarin anticoagulants (dicumarol, warfarin) concomitantly with lesinurad/allopurinol
            • Allopurinol with mercaptopurine or azathioprine
              • Patients taking allopurinol and mercaptopurine or azathioprine require a reduction in dose to approximately one third to one quarter of the usual dose of mercaptopurine or azathioprine
              • Subsequent dose adjustments of mercaptopurine or azathioprine should be made on the basis of therapeutic response and the appearance of toxic effects; closely monitor therapeutic response and appearance of toxicity



            No available human data on use of lesinurad/allopurinol or lesinurad in pregnant women to inform a drug-associated risk of adverse developmental outcomes. Limited published data on allopurinol use in pregnant women do not demonstrate a clear pattern or increase in frequency of adverse development outcomes

            Animal Data

            • Lesinurad
              • In an embryofetal development study in pregnant rats dosed during the period of organogenesis from gestation days 6-17, lesinurad was not teratogenic and had no affect fetal development or survival at exposures up to ~45 times the maximum recommended human dosage (MRHD) (on an AUC basis at maternal oral doses up to 300 mg/kg/day)
              • In an embryofetal development study in pregnant rabbits dosed during the period of organogenesis from gestation days 7-20, lesinurad was not teratogenic and did not affect fetal development at exposures up to ~10 times the MRHD (on an AUC basis at maternal oral doses up to 75 mg/kg/day); severe maternal toxicity, including mortality, was observed in rats and rabbits at exposures equal to or greater than ~45 and 4 times the MRHD (on an AUC basis at maternal oral doses of 300 mg/kg/day in rats and 25 mg/kg/day and higher in rabbits), respectively
            • Allopurinol
              • In embryofetal development studies with pregnant rats or rabbits, allopurinol administered during the period of organogenesis (gestation days 8–16) was not teratogenic or fetotoxic in either species at doses up to ~6 times the MRHD (on a mg/m2 basis at maternal oral doses up to 200 mg/kg/day in rats and 100 mg/kg/day in rabbits)
              • However, in an embryofetal development study with pregnant mice, single intraperitoneal doses of allopurinol on gestation days 10 or 13 produced significant increases in fetal deaths and teratogenic effects, including external and skeletal malformations, at 0.8 times the MRHD and higher (on a mg/m2 basis at maternal intraperitoneal doses of 50 or 100 mg/kg); it is uncertain whether the findings in mice represented a fetal effect or an effect secondary to maternal toxicity.


            Unknown if distributed in human breast milk

            Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition

            Pregnancy Categories

            A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA: Information not available.



            Mechanism of Action

            Lesinurad: Selective uric acid reabsorption inhibitor (SURI); it acts by inhibiting the urate transporter, URAT1, which is responsible for the majority of the renal reabsorption of uric acid; it also inhibits organic anion transporter 4 (OAT4), a uric acid transporter associated with diuretic-induced hyperuricemia

            Allopurinol: Xanthine oxidase inhibitor that inhibits conversion of hypoxanthine to xanthine to uric acid; decreases production of uric acid without disrupting synthesis of vital purines



            • Bioavailability: ~100% (monotherapy)
            • Peak plasma time: 1-4 hr (single dose)
            • Administration with a high-fat meal, decreases plasma concentration of lesinurad compared with fasted state


            • Peak plasma time: 1-4 hr (allopurinol and oxypurinol)
            • Peak plasma concentration, single 300 mg dose: 3 mcg/mL (allopurinol); 6.5 mcg/mL (oxypurinol)


            Protein bound: 98% (lesinurad)

            Vd: ~20 L (lesinurad)


            Lesinurad undergoes oxidative metabolism mainly via the polymorphic cytochrome CYP2C9 enzyme; metabolites are not known to contribute to the uric-acid lowering effects of lesinurad; caution with use in CYP2C9 poor metabolizers, and in patients taking moderate CYP2C9 inhibitors; see Cautions

            Allopurinol is metabolized to oxypurinol (alloxanthine), which also is a xanthine oxidase inhibitor


            Half-life: 5 hr (lesinurad); 1-2 hr (allopurinol); ~26 hr (oxypurinol)

            Clearance: 6L/hr (lesinurad)

            Allopurinol is cleared essentially by glomerular filtration; oxypurinol is reabsorbed in the kidney tubules similarly to the reabsorption of uric acid

            Excretion: Feces (20%, allopurinol)


            Caution with CYP2C9 poor metabolizers



            Oral Administration

            Take PO qDay in the morning with food and water

            Instruct patient to stay well hydrated (eg, 2 liters of liquid per day)


            Store at 20-25°C (68-77°F); excursions permitted from 15-30°C (59-86°F)



            No images available for this drug.

            Patient Handout

            A Patient Handout is not currently available for this monograph.
            Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.